SEC Form 4 · accession 0001003642-17-000029
Impax Laboratories, LLC · IPXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Bisaro
Officer — President and CEO · Director
Period of report
Mar 27, 2017
Accepted (ET)
Mar 29, 2017 · 6:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001003642
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.70 | Mar 27, 2017 | A | 850,000 | A | — | Mar 27, 2027 | Common Stock | 850,000 | 850,000 | D |
Explanation of responses
- F1The option vests in four equal installments beginning on March 27, 2018, which is the first anniversary of the grant date.
Remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.